Physician profile
Mac A Bowman
NPI 1972549046
$9,560.91
in general payments reported to CMS, 2019-2025
39 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,740 · 2020: $655 · 2021: $626 · 2022: $1,096 · 2023: $1,580 · 2024: $2,356 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,338 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,338.08 |
| Education | $105.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,430.19 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Novartis Pharmaceuticals Corporation | $1,170.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $761.72 | 2019-2025 | Jardiance |
| Amgen INC. | $693.03 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $678.79 | 2019-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $540.51 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $531.87 | 2019-2025 | Lifevest |
| Pfizer INC. | $474.66 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $426.76 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $420.87 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $380.09 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $305.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $258.87 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.09 | 2019-2025 | |
| Esperion Therapeutics, INC. | $185.48 | 2020-2025 | Nexletol |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mac Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.